The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo --
-- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against SARS-CoV-2 --
-- SCB-2019 is among the first COVID-19 vaccines to demonstrate ability to significantly reduce SARS-CoV-2 transmission prospectively in a clinical study to date --
https://finance.yahoo.com/news/clover-vaccine-candidate-reduced-household-102800002.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.